Quidel Corp
NASDAQ:QDEL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Quidel Corp
Total Receivables
Quidel Corp
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Quidel Corp
NASDAQ:QDEL
|
Total Receivables
$571.7m
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
41%
|
|
|
Haemonetics Corp
NYSE:HAE
|
Total Receivables
$195.7m
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
3%
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Total Receivables
$180.5m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Total Receivables
$1.2B
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
22%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Total Receivables
$374m
|
CAGR 3-Years
21%
|
CAGR 5-Years
47%
|
CAGR 10-Years
26%
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Total Receivables
$223.6m
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
11%
|
|
Quidel Corp
Glance View
Quidel Corporation, a player in the diagnostic healthcare industry, has steadily navigated the labyrinth of medical innovation, carving out a niche in rapid diagnostic testing. Born out of a mission to streamline the process of disease detection, Quidel has leveraged biotechnology to develop fast, reliable diagnostic solutions that address widespread health issues. This company’s arsenal includes tests for infectious diseases, reproductive health, and autoimmune disorders—each meticulously designed to expedite the diagnostic process while maintaining a stringent commitment to accuracy. By fostering partnerships with healthcare providers and aligning with technological advancements, Quidel has positioned itself as indispensable in the clinic setting, where swift decision-making can significantly impact patient care. At the heart of Quidel's business model is its focus on providing tangible value to both healthcare professionals and patients. The company generates revenue primarily through the sale of its diagnostic products, which are utilized in settings ranging from small clinics to large hospital networks. Quidel's innovative platforms, like the Sofia and Solana systems, are lauded for their efficiency and ease of use, attributes that resonate particularly well in medical environments under pressure to deliver fast and effective results. By effectively converting scientific expertise into practical and user-friendly applications, Quidel not only enhances patient outcomes but also fortifies its financial standing within the competitive landscape of medical diagnostics.
See Also
What is Quidel Corp's Total Receivables?
Total Receivables
571.7m
USD
Based on the financial report for Dec 28, 2025, Quidel Corp's Total Receivables amounts to 571.7m USD.
What is Quidel Corp's Total Receivables growth rate?
Total Receivables CAGR 10Y
41%
Over the last year, the Total Receivables growth was 27%. The average annual Total Receivables growth rates for Quidel Corp have been 2% over the past three years , 2% over the past five years , and 41% over the past ten years .